SEC Form 4 · accession 0001209191-18-063953
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark W Hahn
Officer — Chief Financial Officer
Period of report
Dec 19, 2018
Accepted (ET)
Dec 21, 2018 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 19, 2018 | P | 2,500 | $6.28 | A | 2,500 | D |
Table II — derivative securities
No Table II lines on this filing.